TNGX
Tango Therapeutics, Inc.
Tango Therapeutics, Inc. (TNGX) has 6 SEC Form 4 filings (10 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Jul 2, 2026.
Insiders have net sold $1.4M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Malte Peters
- Employees:155
- HQ:Boston, MA, US
- IPO:2020-09-03
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.4M
reported sales (SEC code S)
Unique Insiders
1
in the rolling window
Market Cap
$4.0B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| President, R&D | Sale | 27,000 | $799K | Jul 2 | SEC ↗ | |
Crystal AdamFirst filing | President, R&D | Sale | 27,000 | $573K | May 5 | SEC ↗ |
Related companies
Tango Therapeutics, Inc. is in the Healthcare sector.